Objective To analyze the specificity of amyloid precursor protein (APP) and brain derived neurotrophic factor (BDNF) in peripheral blood in children with autism spectrum disorder (ASD), so as to explore the biomarkers for early diagnosis of ASD. Method A total of 103 ASD children,25 children with intellectual disability (ID),25 children with attention deficit hyperactivity disorder (ADHD) and 78 healthy children in Hubei Provincial Maternal and Child Health Care Hospital were enrolled in this study from January 2013 to December 2016. And the plasma total sAPP, sAPP-α, sAPP-β and brain-derived neurotrophic factor (BDNF) of participants were tested by sensitive enzyme-linked immunosorbent assay method, and were compared among those four groups. Results The levels of sAPP and sAPP-α among ASD, ID, ADHD and normal control groups were significantly different (Z=86.17,39.01,both P＜0.001), while the difference on the levels of sAPP-β and BDNF among those four groups were not significant (both P＞0.05). Conclusions Considering the specific change of APP in ASD children, APP may be a promising biomarker in the early diagnosis of ASD.
Key words
autism spectrum disorder /
amyloid precursor protein /
brain derived neurotrophic factor /
attention deficit hyperactivity disorder /
intellectual disability
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators,Centers for Disease Control and Prevention (CDC).Prevalence of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network,11 sites,United States[J].MMWR Surveill Summ,2014,63(2):1-21.
[2] Lohr WD,Tanguay P. DSM-5 and proposed changes to the diagnosis of autism[J].Pediatr Ann,2013,42(4):161-166.
[3] Mugzach O,Peleg M,Bagley SC,et al. An ontology for autism spectrum disorder (ASD) to infer ASD phenotypes from Autism Diagnostic Interview-Revised data [J].Biomed Inform,2015,56:333-347.
[4] Dawson G,Bernier R.A quarter century of progress on the early detection and treatment of autism spectrum disorder[J].Dev Psychopathol,2013,25(2):1455-1472.
[5] Harrington JW,Allen K. The clinician's guide to autism[J].Pediatr Rev,2014,35(2):62-78.
[6] Wang H,Xu HQ,Wang XY,et al. Amyloid precursor protein associates with autism spectrum disorder: a potential candidate biomarker for early screening[J].Int J Clin Exp Med,2016,9(11):22259-22266.
[7] Taurines R,Segura M,Schecklmann M,et al. Altered peripheral DNFmRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder[J].J of Neural Transm,2014,121(9):1117-1128.
[8] Olsson MB,Westerlund J,Lundström S,et al. “Recovery” from the diagnosis of autismand then? [J].Neuropsychiatr Dis Treat,2015,11(4):999-1005.
[9] Nelson KB,Grether JK,Croen LA,et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation [J]. Ann Neurol,2001,49:597-606.
[10] Philippe A,Guilloud-Bataille M,Martinez M,et al.Analysis of ten candidate genes in autism by association and linkage[J].Am J Med Genet,2002,114(2):125-128.
[11] Laila Y,Alvadh I. Relationship between sonic hedgehogprotein,brain-derived neurotrophic factor and oxidative stress inautism spectrum disorders[J]. Neurochem Res,2012,37(2):394-400.
[12] Webb RL,Murphy MP.β-Secretases,alzheimer′s disease,and Down syndrome[J].Curr Gerontol Geriatr Res,2012,28(2):362839.
[13] Golde TE. Alzheimer disease: host immune defence,amyloid-beta peptide and Alzheimer disease [J]. Nat Rev Neurol,2016,12(8):433-444.
[14] Bailey AR,Giunta BN,Obregon D,et al.Peripheral biomarkers in autism:secreted amyloid precursor protein-α as a probable key player in early diagnosis [J].Int J Clin Exp Med,2008,1(4):338-344.
[15] Ray B,Long JM,Sokol DK,et al.Increased secreted amyloid precursor protein-a(sAPPa) in severe autism:proposal of a specific,anabolic pathway and putative biomarker [J].PLoS One,2011,6(6):e20405.
PDF(619 KB)
